Clopidogrel is used with aspirin as a standard combined treatment in patients with acute coronary syndrome. A proton pump inhibitor (PPI) is often administered to patients receiving antiplatelet therapy. However, PPI use with clopidogrel was recently shown to result in increased risk of major cardiovascular events when compared to clopidogrel use alone. Therefore, the aim of the present study was to evaluate the effects of omeprazole, a PPI, on the antiplatelet effect of clopidogrel.
T he use of powerful antiplatelet agents is increasing as drug-eluting stents (DES) become more widely used. Clopidogrel is used with aspirin as a standard combined treatment for secondary prevention of acute coronary syndrome and prevention of stent thrombosis in patients with coronary stents. [1] [2] [3] Despite its proven benefit, the individual patient responses to clopidogrel show considerable heterogeneity. Recent data show that an adequate antiplatelet effect is not achieved in 4 -30% of the patients on clopidogrel, suggesting that many patients are resistant or only partially responsive to the antiplatelet effect of the drug. [4] [5] [6] [7] A number of different factors may influence the antiplatelet effect of clopidogrel. Drug interaction could be one important factor. Clopidogrel is an inactive prodrug that requires in vivo conversion to an active metabolite by the cytochrome P450 3A4 enzyme system in the liver. 8, 9) Therefore, the drug component that involves the cytochrome P450 enzyme system may be the cause of clopidogrel resistance. A proton pump inhibitor (PPI) is often administered to patients receiving antiplatelet therapy for treating gastrointestinal symptoms or bleeding. However, results from a recent large population-based study have suggested that PPI use with clopidogrel results in increased risk of major cardiovascular events as compared to clopidogrel use alone. 10) In this study, to evaluate the interaction between clopidogrel and omeprazole, we compared the antiplatelet effect of clopidogrel when administered alone with that when clopidogrel was coadministered with the PPI omeprazole.
Methods
Subjects and study protocol: We recruited 20 healthy volunteers with no history of drug treatment in the previous 3 months. Exclusion criteria were previous treatment with clopidogrel or a PPI, history of thrombocytopenia or bleeding disorder, liver disease or increase of liver enzymes over 2 times higher the normal upper limit, gastrointestinal ulcer, or pregnancy. All subjects gave informed consent according to a protocol approved by the institutional review board.
The subjects were divided into two groups of 10 subjects each. One group received an initial loading dose of clopidogrel 300 mg and, after 24 hours, these subjects were administered a dosage of 75 mg/day of clopidogrel and a placebo for the next 14 days. After a 3 week interval, they were administered a clopidogrel loading dose of 300 mg again, followed 24 hours later with a dosage of 75 mg/day of clopidogrel and 20 mg/day of omeprazole for 14 days.
The other group was treated in reverse order; the subjects received the combination of omeprazole and clopidogrel first followed by administration of clopidogrel with the placebo after 3 weeks. Blood samples were taken at baseline, after 24 hours, and on day 7 and day 14, and platelet activity was measured (Figure 1 ). Data collection: Complete blood count and blood chemistry analyses, including liver and renal function tests, were performed before and two weeks after the therapy. The samples were obtained by antecubital venipuncture, and the initial 3 -4 mL of blood was discarded to avoid spontaneous platelet activation. The second samples were collected in tubes containing 3.2% citrate for the rapid platelet-function assay.
Platelet reactivity was assessed using a VerifyNow-P2Y12 assay (Accumetrics, San Diego, CA). The VerifyNow-P2Y12 system is a rapid platelet-function, cartridgebased assay designed to directly measure the effects of clopidogrel on the P2Y12 receptor.
11) The results are expressed as the P2Y12 reaction unit (PRU) and percentage inhibition. The PRU indicates the amount of P2Y12 receptor mediated aggregation specific to platelets and is calculated as a function of the rate and extent of platelet aggregation in the ADP-channel. Percentage inhibition is the percent change from baseline aggregation and is calculated from the PRU result and estimated baseline result, which is an independent measure based on the rate and extent of platelet aggregation in the thrombin receptor activating peptide (TRAP) channel. Therefore, percentage inhibition = (1-PRU/estimated baseline) × 100.
Both placebo and omeprazole were administered during clopidogrel treatment and PRU and percentage inhibition were compared before and 24 hours after the treatment, on day 7 and on day14. Statistical analysis: Continuous variables are reported as the mean ± standard deviation and categorical variables are presented as frequencies and percentage. Intergroup analysis was performed with the independent t-test, chi-square test, and Fisher's exact test using SPSS 11.0 for Windows (SPSS Inc., Chicago, IL). To compare the PRU and percentage inhibition before and after the omeprazole treatment, we used a paired t test. Statistical significance was set at P < 0.05.
Results
The average age of the subjects was 33 ± 7 years. There were 12 males (60%) and 5 subjects were current smokers. No patient had diabetes or hypertension or was on any medication. Platelet level, liver function, and kidney function showed no differences between the measurements before and 14 days after the treatment (Table I ). Table II presents the entire time course of PRU in each group. The PRU in the omeprazole treated group was 355.2 ± 65.5 before treatment, 294.5 ± 59.4 after 24 hours, 264.8 ± 61.1 on day 7, and 281.3 ± 54.0 on day 14, while that in the omeprazole untreated group was 362.2 ± 51.2 before treatment, 288.8 ± 94.7 after 24 hours, 257.2 ± 76.1 on day 7, and 240.0 ± 72.2 on day 14 (P = 0.048, day 14). The percentage inhibition was 5.5 ± 5.5% before treatment, 21.7 ± 10.7% after 24 hours, 28.5 ± 11.1% on day 7, and 22.7 ± 9.9% on day 14 following omeprazole treatment, and 6.7 ± 6.2% before treatment, 26.4 ± 20.2% after 24 hours, 31.5 ± 20.7% on day 7, and 35.1 ± 18.7% on day 14 without omeprazole treatment (P = 0.014, day 14) (Figure 2) .
Seven patients showed an increase in percentage inhibition after 2 weeks of treatment that was less than 20% higher than the baseline level, however, this result was unrelated to the omeprazole treatment. During the study period, 2 cases of slight bruising and 2 cases of nausea were observed, but no serious adverse effect occurred in any patient.
Discussion
Treatment with omeprazole significantly increased the PRU and significantly reduced the percentage inhibition measured on day 14, suggesting that omeprazole significantly decreased the inhibitory effect of clopidogrel on platelet activation.
Dual antiplatelet therapy for 12 months is currently believed to be mandatory after DES insertion for the prevention of stent thrombosis. 12) However, recent data indicate that an adequate antiplatelet effect is not achieved in 4 -30% of patients taking clopidogrel. [4] [5] [6] [7] Small-scale investigations have suggested that clopidogrel resistance may be associated with a heightened risk of adverse clinical events. [13] [14] [15] [16] The mechanisms underlying clopidogrel resistance are still controversial. Possible mechanisms include drug interaction involving the cytochrome P450 enzyme, insulin resistance, poor bioavailability, and polymorphisms of the cytochrome P450 3A and P2Y12 receptor genes. [17] [18] [19] Clopidogrel metabolism is associated with the cytochrome P450 3A4 enzyme system. In fact, human cytochrome P450 3A4 is the most abundant hepatic and intestinal phase I enzyme and metabolizes approximately 50% of the drugs on the market. Clinically important CYP3A4 inhibitors identified thus far mainly include macrolide antibiotics (e.g., clarithromycin, and erythromycin), anti-HIV agents (e.g., ritonavir and delavirdine), antidepressants (e.g., fluoxetine and fluvoxamine), calcium channel blockers (e.g., verapamil and diltiazem), steroids and their modulators (e.g., gestodene and mifepristone), and several herbal and dietary components. 17) Omeprazole is eliminated by the hepatic route, and cytochrome 2C19 is involved in the metabolism of omeprazole and other PPIs. Cytochrome 2C19 does not appear to be a major hepatic pathway for clopidogrel metabolism, and its influence on clopidogrel-induced platelet inhibition may be limited. 20) However, the results of our study have demonstrated that omeprazole significantly inhibits the antiplatelet effect of clopidogrel. This finding was also observed in a recent prospective, randomized study. Gilard, et al have reported that omeprazole significantly decreases the inhibitory effect of clopidogrel on the platelet P2Y12 receptor, assessed by the vasodilator-stimulated phosphoprotein phosphorylation test. 21) The difference in the incidences of genetic polymorphism may be related to the fact that their observation was based on results from different groups of patients. However, such a hypothesis was not justifiable in our study because we conducted the tests on the same subjects. A large population-based study showed an odds ratio of 1.79 for major cardiovascular events within 1 year among patients receiving both PPIs and clopidogrel compared with those on clopidogrel treatment alone. 10) This study sug- gested that omeprazole and rabeprazole are more associated with adverse outcomes than the other PPIs. Siller-Matula, et al reported that pantoprazole and esomeprazole are not associated with an impaired response to clopidogrel, in contrast to the negative omeprazole-clopidogrel interaction. 22) Therefore, the decreased antiplatelet effect of clopidogrel may be influenced by only omeprazole and not all PPIs. Although the underlying mechanism is unknown, it is obvious that omeprazole has an inhibitory effect on clopidogrel.
The limitations of our study include the small number of subjects and the single blind protocol. Moreover, we did not conduct any mechanistic investigations. In a real clinical setting, patients are prescribed clopidogrel with aspirin, cilostazole, or another antiplatelet agent, but we did not test such a situation. Accordingly, further clinical and experimental studies are required.
In conclusion, omeprazole reduces the antiplatelet effect of clopidogrel. Therefore, omeprazole administration to patients on clopidogrel medication must be planned more carefully.
